SLC25A16 Antikörper (N-Term)
Kurzübersicht für SLC25A16 Antikörper (N-Term) (ABIN630321)
Target
Alle SLC25A16 Antikörper anzeigenReaktivität
Wirt
Klonalität
Konjugat
Applikation
-
-
Bindungsspezifität
- N-Term
-
Spezifität
- SLC25 A16 antibody was raised against the N terminal of SLC25 16
-
Aufreinigung
- Purified
-
Immunogen
- SLC25 A16 antibody was raised using the N terminal of SLC25 16 corresponding to a region with amino acids KTTVAPLDRVKVLLQAHNHHYKHLGVFSALRAVPQKEGFLGLYKGNGAMM
-
-
-
-
Applikationshinweise
-
WB: 5 µg/mL
Optimal conditions should be determined by the investigator. -
Kommentare
-
SLC25A16 Blocking Peptide, (ABIN940083), is also available for use as a blocking control in assays to test for specificity of this SLC25A16 antibody
-
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Format
- Lyophilized
-
Rekonstitution
- Lyophilized powder. Add distilled water for a 1 mg/mL concentration of SLC20 16 antibody in PBS
-
Konzentration
- Lot specific
-
Buffer
- PBS
-
Handhabung
-
Avoid repeated freeze/thaw cycles.
Dilute only prior to immediate use. -
Lagerung
- 4 °C/-20 °C
-
Informationen zur Lagerung
- Store at 2-8 °C for short periods. For longer periods of storage, store at -20 °C.
-
-
- SLC25A16 (Solute Carrier Family 25 (Mitochondrial Carrier, Graves Disease Autoantigen), Member 16 (SLC25A16))
-
Andere Bezeichnung
- SLC25A16
-
Hintergrund
- SLC25A16 is a protein that contains three tandemly repeated mitochondrial carrier protein domains. The protein is localized in the inner membrane and facilitates the rapid transport and exchange of molecules between the cytosol and the mitochondrial matrix space. SLC25A16 gene has a possible role in Graves' disease.
-
Molekulargewicht
- 36 kDa (MW of target protein)
Target
-